Kymera Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Nello Mainolfi
- Full Time Employees
- 253
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 500 North Beacon Street Watertown MA United States of America 02472
- IPO Date
- Aug 21, 2020
- CIK
- 0001815442
- Website
- kymeratx.com
- Similar Companies
- Business
- Kymera Therapeutics, Inc. (KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics utilizing targeted protein degradation to selectively eliminate disease-causing proteins by harnessing the body's natural protein degradation machinery; its proprietary Pegasus platform supports a pipeline focused primarily on immunology and inflammation disorders, with additional programs in oncology. The company offers investigational oral degraders including KT-621, a first-in-class STAT6 degrader in Phase 1 trials for Th2-mediated diseases such as atopic dermatitis, asthma, chronic obstructive pulmonary disease, prurigo nodularis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, bullous pemphigoid and chronic spontaneous urticaria; KT-579, an IRF5 degrader in IND-enabling studies for autoimmune conditions including lupus, Sjögren’s syndrome, rheumatoid arthritis, inflammatory bowel disease, systemic sclerosis and dermatomyositis; and KT-485 (SAR447971), a second-generation IRAK4 degrader prioritized by partner Sanofi for clinical advancement in immuno-inflammatory diseases like hidradenitis suppurativa, atopic dermatitis, psoriasis, asthma and others. It also advances a CDK2 molecular glue degrader program in collaboration with Gilead Sciences targeting oncology indications such as breast cancer and other solid tumors where CCNE1 amplification drives resistance to CDK4/6 inhibitors. Founded in 2015 and headquartered in Watertown, Massachusetts, Kymera operates globally with partnerships including Sanofi for IRAK4 degraders outside oncology, providing milestone payments up to $975 million, U.S. co-commercialization option and profit-sharing, and royalties elsewhere; and Gilead for the CDK2 program, offering up to $750 million including $85 million upfront and option fees plus tiered royalties. Recent developments encompass the June 2025 Gilead alliance for CDK2, Sanofi's prioritization of KT-485 for clinical studies by year-end 2025 with a related $20 million preclinical milestone to Kymera, expansion of the immunology pipeline with the IRF5 program (KT-579) announced in May 2025 targeting rheumatic and autoimmune diseases, and positive Phase 1 data for KT-621 and prior IRAK4 degrader KT-474.
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
Kymera's CEO Sold $6 Million in Stock After a 170% Run
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
Kymera Therapeutics: Why It May Be Time To Jump On The Bandwagon (Upgrade)
Kymera: Building Toward A Defining 2H26 Moment
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
Why Kymera Therapeutics Stock Popped This Week
Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study
Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?
Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
Biotech ETF Index Surges 10% After Rebalance
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
Kymera Therapeutics Appoints Felix J. Baker, Ph.D.
Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study